clinical trial · NCT07331389
A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·phase1·recruiting·n = 111
Overweight SubjectHealthy SubjectsMetforminEmpagliflozinMidazolamValsartanWarfarinHDM1002
brief summary
The purpose of this study is to characterize the drug-drug intereaction of HDM1002 and metformin, empagliflozin, midazolam, valsartan, and warfarin in overweight/obese adult subjects. The safety and tolerability of HDM1002 with metformin, empagliflozin, midazolam, valsartan, and warfarin when given separately or together will also be evaluated
started
Sep 24, 2025
primary completion
Jan 12, 2026
completion
Jun 13, 2026
last updated
Jan 9, 2026
official title
A Phase I, Single-center, Open-Label, Single-Arm, Fixed-Sequence Study to Evaluate the Drug-Drug Interaction of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin in Overweight/Obese Adult Chinese Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol